EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Antihypertensive Efficacy, Safety, and Adherence After Switching From a Free Combination of Bisoprolol/Metoprolol and Amlodipine to Bisoprolol/Amlodipine FDC Tablets (5/5 mg) in Chinese Patients With Hypertension

Ning Wang, Xiaoyang Zhou, Jianmiao Han, Jun Jiang, Linlin Ma, Guixin Liu, Rufei Liu, Yawei Kong, Yiping Tang, Wenyuan Jiang, Yuxuan Wei, Wenli Cheng

The Journal of Clinical Hypertension · 2026-07 · 28 (7)

DOI: 10.1111/jch.70315 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Hypertension, online erschienen am 01.07.2026. Verfasst von Ning Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Amlodipine, Antihypertensive Agents, Bisoprolol, Hypertension. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Anzhen Hospital and Merck Serono Co., Ltd., Beijing, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension is a leading chronic disease globally, with rising prevalence in China. A considerable number of hypertension patients struggle to achieve target blood pressure levels with monotherapy alone. The bisoprolol/amlodipine FDC shows promise for blood pressure control and adherence, whereas clinical evidence for Chinese patients is limited. This prospective study evaluated efficacy and safety in patients inadequately controlled by free combination of bisoprolol/metoprolol and amlodipine. In a prospective trial spanning 12 weeks across multiple centers, 78 patients were enrolled who failed 4‐week free combinations (e.g., bisoprolol 2.5 mg/day or metoprolol formulations + amlodipine/levamlodipine). Inclusion required office systolic blood pressure (SBP) ≥140 mmHg and/or office diastolic blood pressure (DBP) ≥90 mmHg, with resting heart rate (RHR) ≥70 beats per minute (bpm). Assessments included office BP (OBP) at 4th, 8th, 12th weeks; home BP (HBP) at 0, 1st, 5th, 9th weeks; ambulatory BP at 0, 11 weeks; and time in target range (TTR) at 12 weeks. Patients averaged 49±12.4 years, 73.1% male. After 1 week, home SBP decreased by 6.6 mmHg, DBP by 4.2 mmHg, RHR by 5.5 bpm (all p < 0.0001). OBP significantly reduced at 4 and 8 weeks. By 12 weeks, office SBP dropped by 13.9 mmHg, DBP by 11.2 mmHg, and RHR by 11.3 bpm (all p < 0.0001). The mean Clinic TTR significantly increased by 47.9 percentage points (from 31.3% to 79.2%, p < 0.0001), with the proportion of patients achieving Clinic TTR >70% rising from 19.2% to 66.7% ( p < 0.0001). At 11 weeks, ambulatory SBP and HR fell substantially ( p < 0.001), and Ambulatory TTR also significantly improved across 24‐hour, daytime, and nighttime periods. Bisoprolol/amlodipine FDC is safe and effective for Chinese patients with hypertension not adequately controlled by free combinations of bisoprolol/metoprolol and amlodipine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmlodipineAntihypertensive AgentsBisoprololHypertensionMetoprololAgedFemaleHumansMaleMiddle AgedBlood PressureBlood Pressure Monitoring, AmbulatoryChinaDrug CombinationsDrug Therapy, CombinationProspective StudiesTabletsTreatment OutcomeAdolescentYoung AdultAdultEast Asian People

Stichwörter der Autor:innen

adherenceamlodipine/bisoprololdrug combinationsefficacyhypertensionsafety

Substanzen

AmlodipineAntihypertensive AgentsBisoprololDrug CombinationsMetoprololTablets

Autor:innen und Institutionen

  • Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Renmin Hospital of Wuhan University, Wuhan, China.
  • The Third Hospital of Shijiazhuang, Shijiazhuang, China.
  • The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Förderung

  • Beijing Anzhen Hospital and Merck Serono Co., Ltd., Beijing, China

Zitieren

APA

Wang, N., Zhou, X., Han, J., Jiang, J., Ma, L., Liu, G., Liu, R., Kong, Y., Tang, Y., Jiang, W., Wei, Y., & Cheng, W. (2026). Antihypertensive Efficacy, Safety, and Adherence After Switching From a Free Combination of Bisoprolol/Metoprolol and Amlodipine to Bisoprolol/Amlodipine FDC Tablets (5/5 mg) in Chinese Patients With Hypertension. The Journal of Clinical Hypertension, 28(7). https://doi.org/10.1111/jch.70315

Vancouver

Wang N, Zhou X, Han J, Jiang J, Ma L, Liu G, et al. Antihypertensive Efficacy, Safety, and Adherence After Switching From a Free Combination of Bisoprolol/Metoprolol and Amlodipine to Bisoprolol/Amlodipine FDC Tablets (5/5 mg) in Chinese Patients With Hypertension. The Journal of Clinical Hypertension. 2026;28(7). doi:10.1111/jch.70315

BibTeX
@article{Wang2026,
  author = {Wang, Ning and Zhou, Xiaoyang and Han, Jianmiao and Jiang, Jun and Ma, Linlin and Liu, Guixin and Liu, Rufei and Kong, Yawei and Tang, Yiping and Jiang, Wenyuan and Wei, Yuxuan and Cheng, Wenli},
  title = {Antihypertensive Efficacy, Safety, and Adherence After Switching From a Free Combination of Bisoprolol/Metoprolol and Amlodipine to Bisoprolol/Amlodipine FDC Tablets (5/5 mg) in Chinese Patients With Hypertension},
  journal = {The Journal of Clinical Hypertension},
  year = {2026},
  volume = {28},
  number = {7},
  doi = {10.1111/jch.70315}
}
Kostenlos starten →